Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 12/2013

01.12.2013 | Hypertension (M Sorrentino, Section Editor)

Medical Treatment of Hypertension in Patients with Heart Failure with Preserved Ejection Fraction

verfasst von: Richard G. Kiel, Prakash Deedwania

Erschienen in: Current Cardiology Reports | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Heart failure with preserved ejection fraction (HFPEF) has become an increasingly common problem, accounting for as many as half of all diagnoses of heart failure. Hypertension has been shown to be a major risk factor for the development of HPEF, and the treatment of hypertension is key to both preventing the development of HFPEF as well as mitigating its impact on our health care system. While numerous studies have looked at using various classes of antihypertensive medications to treat HFPEF, there are still no well validated treatment strategies which have shown a significant mortality benefit. As a result, when choosing an antihypertensive medication to treat or prevent HFPEF, it is important to tailor the choice of antihypertensive medication to an individual patient’s specific symptoms and comorbidities.
Literatur
1.
American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46.
2.
Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function. Circulation. 2002;105(11):1387.
3.
Davis BR et al. Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118(22):2259–67.
4.
•• Piller LB et al. Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation. 2011;124(17):1811–8. The ALLHAT study is one of the strongest studies to date comparing the efficacy of various classes of antihypertensives, evaluating the relative efficacy of chlorthalidone, amlodipine, and lisinopril.
5.
Faris R, Flather MD, Purcell H, Poole-Wilson PA, Coats AJ. 434 Diuretics for heart failure. Cochrane Database Syst Rev. 2012;2: 435 CD003838.
6.
Verdecchia P et al. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens. 2006;19:493–9.
7.
Okin PM et al. Losartan intervention for endpoint reduction in hypertension study investigators: regression of electrogardiographic left ventricular hypertrophy by losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) study. Circulation. 2003;108:684–90.
8.
Dahlof B et al. for the LIFE study group: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003.
9.
Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment of left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41.
10.
Burns J et al. Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance. J Hypertens. 2012;30:2039–46.
11.
Shaw RV, Akshay SD, Givertz MM. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with with heart failure and preserved ejection fraction: a systematic review and meta-analysis. J Card Fail. 2010;16(3):260–7.
12.
Flatcher MD et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215.CrossRef
13.
• Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction – The Aldo-DHF randomized control trial. JAMA. 2013;309(8):781–91. Aldo-DHF was a highy anticipated study looking at the efficacy of spironolactone on improving outcomes in patents with HFPEF. Ultimately, despite an demonstrated improvement in LV diastolic function the study failed to demonstrate any clinically significant benefits.PubMedCrossRef
14.
Bertram P et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-Left Ventricular Hypertrophy study. Circulation. 2003;108:1831–8.CrossRef
15.
Takeda Y et al. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction. Am J Cardiol. 2004;94(4):448–53.PubMedCrossRef
16.
Hernandez AF, Hammill BG, O’Connor CM, Shulman KA, Curtis LH, Fonarow GC. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Life Saving Treatment in Hospitalized Patients with Heart Failure) registry. J Am Coll Cardiol. 2009;53(2):184.
17.
Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol. 1990;66(12):981–6.
18.
Bonow RO, Dilxizian V, Rosing DR, Maron BJ, Bacharach SL, Green MV. Verapamil-induced improvement in left ventricular diastolic feeling and increased exercise tolerance in patients with hypertrophic cardiomyopathy: short-and long-term effects. Circulation. 1985;72(4):853.
Metadaten
Titel
Medical Treatment of Hypertension in Patients with Heart Failure with Preserved Ejection Fraction
verfasst von
Richard G. Kiel
Prakash Deedwania
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 12/2013
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-013-0428-5

Weitere Artikel der Ausgabe 12/2013

Current Cardiology Reports 12/2013 Zur Ausgabe

Stroke (C Sila, Section Editor)

The Growing Problem of Stroke among Young Adults

Stroke (C Sila, Section Editor)

Acute Hypertensive Response Management in Patients with Acute Stroke

Stroke (C Sila, Section Editor)

Small Vessel Disease and Memory Loss: What the Clinician Needs to Know to Preserve Patients’ Brain Health

Stroke (C Sila, Section Editor)

Cryptogenic Stroke: How to Define It? How to Treat It?

Stroke (C Sila, Section Editor)

Sudden Unexpected Death in Epilepsy or Voodoo Heart: Analysis of Heart/Brain Connections

Stroke (C Sila, Section Editor)

Cerebral Microbleeds and Macrobleeds: Should They Influence Our Recommendations for Antithrombotic Therapies?

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise